CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

Participants were randomized to oral apixaban at a reduced dose (2.5 mg) or a full dose (5.0 mg) twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal ...

Please provide your email address to receive an email when new articles are posted on . Continued anticoagulation is recommended for patients with active cancer and/or ongoing cancer treatment.

They were randomized to double-blind treatment with oral apixaban at a reduced (2.5 mg) or full (5.0 mg) dose twice daily for 12 months. Median time from the index VTE (pulmonary embolism for 75% ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

In-Depth [randomized controlled trial]: This international, double-blind, noninferiority trial enrolled patients with active cancer and VTE who had completed at least 6 months of treatment with ...

or full (5.0 mg) dose twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal recurrent venous thromboembolism, assessed in a noninferiority analysis (margin of ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

In addition, patients receiving the reduced dose experienced a lower incidence of clinically relevant bleeding. Researchers randomly assigned 1,766 patients to receive oral apixaban twice daily at a ...

A case presentation involving a patient with severe, symptomatic iliofemoral deep vein thrombosis and need for urgent ...

Participants were randomly assigned to receive either a reduced (2.5 mg) or full (5.0 mg) dose of apixaban for an additional 12 months. The primary goal was to assess the prevention of recurrent VTE, ...

The OCEANIC-AF trial randomized patients to either the novel factor XIa inhibitor asundexian 50 mg once daily or apixaban 5 mg or 2.5 mg twice daily. The trial was terminated early because asundexian ...